Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report)'s stock price shot up 8.4% on Tuesday . The company traded as high as $15.15 and last traded at $15.66. 256,132 shares changed hands during mid-day trading, a decline of 71% from the average session volume of 881,768 shares. The stock had previously closed at $14.45.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on CAPR. HC Wainwright reissued a "buy" rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research report on Thursday, January 2nd. Cantor Fitzgerald upped their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an "overweight" rating in a research report on Thursday, November 14th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $34.50.
View Our Latest Stock Report on CAPR
Capricor Therapeutics Stock Performance
The firm has a market cap of $699.33 million, a price-to-earnings ratio of -14.51 and a beta of 4.08. The business's 50 day moving average price is $14.37 and its 200-day moving average price is $13.58.
Institutional Investors Weigh In On Capricor Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Capricor Therapeutics during the fourth quarter worth about $462,000. Voloridge Investment Management LLC acquired a new stake in Capricor Therapeutics during the fourth quarter worth about $1,678,000. Woodline Partners LP acquired a new stake in Capricor Therapeutics during the fourth quarter worth about $8,693,000. Two Sigma Investments LP raised its stake in Capricor Therapeutics by 223.6% during the fourth quarter. Two Sigma Investments LP now owns 119,047 shares of the biotechnology company's stock worth $1,643,000 after acquiring an additional 82,254 shares during the period. Finally, Rafferty Asset Management LLC acquired a new stake in Capricor Therapeutics during the fourth quarter worth about $1,743,000. Institutional investors and hedge funds own 21.68% of the company's stock.
Capricor Therapeutics Company Profile
(
Get Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Featured Articles
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
